Your browser doesn't support javascript.
loading
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
Gampenrieder, S P; Dezentjé, V; Lambertini, M; de Nonneville, A; Marhold, M; Le Du, F; Cortés Salgado, A; Alpuim Costa, D; Vaz Batista, M; Chic Ruché, N; Tinchon, C; Petzer, A; Blondeaux, E; Del Mastro, L; Targato, G; Bertucci, F; Gonçalves, A; Viret, F; Bartsch, R; Mannsbart, C; Deleuze, A; Robert, L; Saavedra Serrano, C; Gion Cortés, M; Sampaio-Alves, M; Vitorino, M; Pecen, L; Singer, C; Harbeck, N; Rinnerthaler, G; Greil, R.
Afiliación
  • Gampenrieder SP; Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical Unive
  • Dezentjé V; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lambertini M; Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, Università di Genova, Genova, Italy.
  • de Nonneville A; Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
  • Marhold M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Le Du F; Département d'oncologie médicale, Centre Eugène-Marquis, Rennes, France.
  • Cortés Salgado A; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Alpuim Costa D; Haematology and Oncology Department, CUF Oncologia, Lisbon, Portugal; NOVA Medical School, (NMS), Faculdade de Ciências Médicas (FCM), Lisbon, Portugal; Centro de Medicina Subaquática e Hiperbárica (CMSH), Marinha Portuguesa, Lisbon, Portugal.
  • Vaz Batista M; Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal.
  • Chic Ruché N; Department of Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain.
  • Tinchon C; Department for Haemato-Oncology, LKH Hochsteiermark-Leoben, Leoben, Austria.
  • Petzer A; Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern-Elisabethinen, Linz, Austria.
  • Blondeaux E; U.O. Epidemiology Unit, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy.
  • Del Mastro L; Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, Università di Genova, Genova, Italy.
  • Targato G; Dipartimento di Oncologia, Ospedale Santa Maria della Misericordia di Udine, Udine, Italy.
  • Bertucci F; Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
  • Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
  • Viret F; Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
  • Bartsch R; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Mannsbart C; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Deleuze A; Département d'oncologie médicale, Centre Eugène-Marquis, Rennes, France.
  • Robert L; Département d'oncologie médicale, Centre Eugène-Marquis, Rennes, France.
  • Saavedra Serrano C; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Gion Cortés M; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Sampaio-Alves M; Faculdade de Medicina, Universidade do Porto (FMUP), Oporto, Portugal.
  • Vitorino M; Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal.
  • Pecen L; Institute of Computer Science, Czech Academy of Sciences, Praha, Czech Republic; Faculty of Medicine in Pilsen - Charles University, Pilsen, Czech Republic.
  • Singer C; Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Harbeck N; Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center of the Ludwig-Maximilians-University, Munich, Germany.
  • Rinnerthaler G; Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical Unive
  • Greil R; Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical Unive
ESMO Open ; 8(1): 100747, 2023 02.
Article en En | MEDLINE | ID: mdl-36563519
BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido